Roche committed ₩710 billion (about $485 million) in investment to South Korea over five years to establish the country as a major global hub for clinical trials. The initiative, inked with Korean authorities, targets expanded trial capacity for common and hard‑to‑treat diseases and aims to accelerate development and local access to innovative biopharmaceuticals. Roche said the funds will underpin clinical infrastructure, regulatory engagement and trial execution capabilities while bringing more studies and investigational products to Korean sites. The company and officials cited South Korea’s strong hospital network, experienced investigators and patient pools as competitive advantages. For multinational sponsors, concentrated investment in regional trial ecosystems reduces operational friction and can shorten timelines for patient recruitment, particularly in indications where high‑volume or genetically defined cohorts are needed.